Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man

European Journal of Clinical Pharmacology

Volumn 35, Issue 2, 1988, Pages 151-156

  Coccheri, S ^a   Biagi, G ^a   Legnani, C ^a   Bianchini, B ^a   Grauso, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

defibrotide; fibrinolysis; plasminogen activator; prostacyclin; prostaglandin E2

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; DEFIBROTIDE; PLASMINOGEN ACTIVATOR; PROSTACYCLIN; PROSTAGLANDIN E2;

ADULT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE;

6-KETOPROSTAGLANDIN F1 ALPHA; COMPARATIVE STUDY; DINOPROSTONE; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMAN; INFUSIONS, INTRAVENOUS; MALE; POLYDEOXYRIBONUCLEOTIDES; RANDOM ALLOCATION; THROMBOXANE B2;

EID: 0023800090     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/BF00609244     Document Type: Article

References (31)

1. Antithrombotic activity of polydeoxyribonucleotide of mammalian origin (laboratory code: Fraction P) in experimental animals
2. Pharmacokinetics of Defibrotide and of its profibrinolytic activity in the rabbit
3. Antithrombotic activity of a polydeoxyribonucleotide substance extracted from mammalian organs A possible link with prostacyclin
4. Activation of plasma and vascular fibrinolytic activity by a polydeoxyribonucleotidic substance, Fraction P, in rats and rabbits
5. Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by Defibrotide in the platelet perfused heart
6. Usefulness of Defibrotide in protecting ischemic myocardium from early reperfusion damage
7. Defibrotide, an antithrombotic substance which preserve postsynaptic alpha- and beta-adrenergic function in post acute infarcted rabbit hearts
8. Defibrotide, an antithrombotic substance which prevents myocardial contracture in ischemic rabbit heart
9. Pharmacokinetics of Defibrotide in healthy volunteers
10. The conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid
11. Methods for the evaluation of human fibrinolysis
12. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurement in plasma
13. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma
14. Radioimmunoassay of prostaglandins and thromboxane
15. A thromboxane synthetase inhibitor reorients endoperoxides metabolism in whole blood toward prostacyclin and prostaglandin E2
16. Diurnal variation of components of the fibrinolytic system
17. Diurnal fluctations in the activity of the fast-acting t-PA inhibitor
18. Effect on fibrinolysis of a new antithrombotic agent: Fraction P (Defibrotide). A multicenter trial
19. Effect of Defibrotide administered i.v., i.m. and per os on some fibrinolytic parameters in man. Controlled study versus placebo
20. Some observations in man with a new extractive drug: Defibrotide
21. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease
22. In vivo effects of Defibrotide on platelet cAMP and blood prostanoid levels
23. Role of leukocytes in acute myocardial infarction in anesthetized dogs: Relationship to salvage by antiinflammatory drugs
24. Morphometric and ultrastructural study of experimental venous thrombosis. Effects of Defibrotide, an antithrombotic agent
25. Prostaglandins: Interaction with platelets and polymorphonuclear leukocytes in hemostasis and inflammation
26. Prostacyclin is produced in whole blood
27. Reduction of myocardial infarct size by neutrophil depletion: Effect of duration of occlusion
28. Arachidonic acid, prostaglandins and the kidney
29. Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (Defibrotide): A controlled study
30. Effect of a new antithrombotic agent (Defibrotide) in acute renal failure due to thrombotic microangiopathy